Early Foley Catheter Removal After Diverticular Colovesical Fistula Repair
Launched by KARIM ALAVI · Feb 10, 2022
Trial Information
Current as of August 21, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at the safety of removing a bladder catheter (a tube that helps drain urine) earlier than usual after surgery for a condition called a colovesical fistula, which is an abnormal connection between the bladder and the colon. In this study, patients will have their catheters removed on the third day after surgery, and the results will be compared to historical data from patients who had their catheters removed later. The goal is to see if early removal is safe and beneficial for patients.
To participate in this trial, you need to be an adult aged 18 or older and scheduled for surgery to repair a diverticular colovesical fistula. However, certain individuals are not eligible, such as those with untreated genitourinary cancers or those who have conditions that would prevent them from regaining normal bladder function after surgery. If you join the study, you can expect to have your bladder catheter removed sooner than usual, and you'll be closely monitored to ensure your recovery goes smoothly. This trial is currently recruiting participants, so there is an opportunity to be part of this important research.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Adults aged 18 and over
- • Undergoing surgical repair of diverticular colovesical fistula
- Exclusion Criteria:
- • Patients with active and untreated genitourinary cancers
- • Subjects with known or suspected Inflammatory Bowel Disease as the cause of colovesical fistula.
- • Individuals who are not expected to regain normal bladder function after surgery as defined by either pre-existing bladder dysfunction with chronic indwelling urinary catheter, supra-pubic catheter, or surgical urinary diversion
- • Individuals who require re-operation prior to Foley removal
- • Adults unable to consent
- • Pregnant women
- • Prisoners
- • Individuals who are not yet adults (infants, children, teenagers less than 18 years old)
About Karim Alavi
Karim Alavi is a seasoned clinical trial sponsor with a robust track record in advancing innovative therapeutic solutions through rigorous research and development. With a strong focus on patient-centric approaches, Alavi leads multidisciplinary teams to design and implement clinical studies that adhere to the highest standards of regulatory compliance and ethical considerations. His expertise spans various therapeutic areas, enabling the efficient progression of novel treatments from the laboratory to clinical practice. Committed to fostering collaboration between stakeholders, Karim Alavi strives to enhance the drug development process and improve patient outcomes through scientific excellence and strategic partnerships.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Worcester, Massachusetts, United States
Patients applied
Trial Officials
KArin Alavi, MD, MPH
Principal Investigator
UMass Chan Medical School
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials